ArticleFrontiers in endocrinology2026
Genetic analysis of biopsy-related droplets in patients undergoing PGT-A and its potential application.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Preimplantation genetic testing for aneuploidy (PGT-A) is essential for selecting embryos free from chromosomal abnormalities before transfer. However, challenges such as detection failures, mosaicism, and the limited accuracy of trophectoderm biopsy in representing the full chromosomal status of the blastocyst persist. Therefore, additional genetic information is needed to complement traditional PGT methods. This study investigated whether biopsy-related droplets (BRDs) contain detectable genetic material and evaluated their characteristics and potential clinical applications. Methods: A total of 318 BRDs were collected from 105 patients undergoing PGT-A. These droplets, generated during the biopsy process, underwent genomic DNA amplification and next-generation sequencing to detect copy number variations (CNVs). Results: The nucleic acid content of BRDs showed no significant correlation with blastocyst morphological grade, but was associated with the developmental day and chromosomal ploidy detected by PGT-A. BRDs of non-euploid blastocysts had higher nucleic acid content than those from euploid ones. Among 91 BRDs with successful CNV detection, 80.22% showed chromosomal ploidy results consistent with PGT-A. The clinical pregnancy rate for BRD-identified euploid blastocysts was significantly higher (84.62%) compared to those with failed or undetectable BRD results (58.00%). Notably, 8 of the 9 non-euploid blastocysts identified by BRD testing did not result in pregnancy. Furthermore, for 5 blastocysts that underwent secondary biopsy after initial PGT-A failure, chromosomal ploidy results from BRD analysis and secondary PGT-A were 80% consistent. Conclusion: BRD-based genetic analysis may serve as an auxiliary tool to PGT, improving embryo selection and transfer decisions by providing additional chromosomal insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.